In the more than 40 years since the beginning of the HIV pandemic, we have come a long way from the introduction of modern Antiretroviral Therapy (ART) in 1996 which consisted of multiple pills taken multiple times a day to the newly available option of long-acting injectable ART dosed six times a year. This shift in HIV treatment delivery has been touted as a gamechanger in relation to mitigating the Achilles heel of ART, notably maintaining near-perfect adherence. On this episode of HIV Connect we will explore this new treatment modality and its potential impact on as the science of HIV evolves and is implemented in real-life within clinical settings across the United States.